All News

S

S

S

S

US presidential hopefuls look to comparative effectiveness analysis to address price and access issues

S

S

S

S

A new study ranks Pfizer's anti-smoking drug as number one in generating adverse event reports. That's bad news for Pfizer-but in the long run, what does it really mean?

While pharma groans at the endless stream of layoffs, one headhunting firm has some encouraging news: Pharma might be cutting costs, but it's also hiring.

Can pharma take advantage of new healthcare data storage sites such as Google Health and Microsoft?s Health vault? Everyone?s curious, but no one?s talking.

Feds consider adding an 800 number to television ads for adverse event reporting. Does this shine light on DTC ads while pushing public health goals? Industry is mum on the topic

American Red Cross scores a win against Johnson & Johnson in a legal battle over the use of one of the healthcare?s most recognizable symbols

Revised Prix Galien Brochure

FDA takes the opportunity to remind industry what reminder ads are, as promotional material for Shire's Fosrenol is deemed in violation of advertising rules

In a win-win situation for both companies, Merck gets access to one of the hottest generics firms in the world while Ranbaxy gets a chance to hang with the big boys.

Rather than wait to see which ePedigree legislation becomes law, biotech firm Genzyme has taken the initiative and implemented an electronic track-and-trace program to clamp down on fake meds.

The Hershey Center for Applied Research is bringing social networking to researchers and academics with a new platform that could become a Facebook for the life science community. Does the site, dubbed KnowledgeMesh, have what it takes cut through the Web 2.0 clutter? Pharm Exec takes a closer look.

Join the IMS workshop dedicated to a groundbreaking new approach to marketing.

Prix Galien Sponsorship

Marketers and sales reps feel the brunt of faltering Procrit sales as J&J consolidates its biologics divisions.

Consumer advertising might be taking a hit in the media and Congress, but pharma was all smiles at this year's PhAME Awards as the best DTC campaigns took the spotlight

Still hoping the journal article on your drug's adverse reactions will go unnoticed? Think again. A new partnership between medical journals and physician social networking site Sermo just made chatting about drugs a lot easier.

Tracking business by indication is critical for evaluating market performance and making accurate resource allocations

More patients are demanding drugs--and showing up everywhere form YouTube to the Supreme Court. But to offer access to investigational drugs, companies first need to know the rules

How to stretch that portfolio to make ends meet

FDA is being pressured to get its act together. The agency says it needs more money and more people to get approvals out the door

A plunging currency and other economic turmoil shouldn't phase pharma, right? Yes and no

New bipartisan bill calls for the standardization of an electronic pedigree across the US pharma supply chain. Is this a good thing, or just more work for pharma?